000			02285 a2200589 4500
005			20250518042834.0
264		0	_c20200617
008			202006s 0 0 eng d
022			_a1557-3125
024	7		_a10.1158/1541-7786.MCR-18-0923 _2doi
040			_aNLM _beng _cNLM
100	1		_aHernández-Prat, Anna
245	0	0	_aNovel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models. _h[electronic resource]
260			_bMolecular cancer research : MCR _c09 2019
300			_a1931-1944 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdministration, Oral
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aBenzoxazoles _xadministration & dosage
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Synergism
650	0	4	_aHumans
650	0	4	_aImidazoles _xadministration & dosage
650	0	4	_aMale
650	0	4	_aMechanistic Target of Rapamycin Complex 1 _xantagonists & inhibitors
650	0	4	_aMechanistic Target of Rapamycin Complex 2 _xantagonists & inhibitors
650	0	4	_aMice
650	0	4	_aMorpholines _xadministration & dosage
650	0	4	_aPaclitaxel _xadministration & dosage
650	0	4	_aPyridines _xadministration & dosage
650	0	4	_aPyrimidines _xadministration & dosage
650	0	4	_aUrinary Bladder Neoplasms _xdrug therapy
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aRodriguez-Vida, Alejo
700	1		_aJuanpere-Rodero, Nuria
700	1		_aArpi, Oriol
700	1		_aMenéndez, Silvia
700	1		_aSoria-Jiménez, Luis
700	1		_aMartínez, Alejandro
700	1		_aIarchouk, Natalia
700	1		_aRojo, Federico
700	1		_aAlbanell, Joan
700	1		_aBrake, Rachael
700	1		_aRovira, Ana
700	1		_aBellmunt, Joaquim
773	0		_tMolecular cancer research : MCR _gvol. 17 _gno. 9 _gp. 1931-1944
856	4	0	_uhttps://doi.org/10.1158/1541-7786.MCR-18-0923 _zAvailable from publisher's website
999			_c29760559 _d29760559